Neoplasia/BPH

	AMACR and ZFPL1 serum biomarkers enhance precision in predicting postoperative prostate cancer outcomes. Front Oncol Yang L, Lv R, Liu Z, Chen G, Gu G. PMID: 41783436 [PubMed - in process]
	Correction to 'Quercetin Can Be a More Reliable Treatment for Metastatic Prostate Cancer Than the Localized Disease: An InÂ Vitro Study'. J Cell Mol Med PMID: 41782225 [PubMed - in process]
	Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study. BJU Int Palshof FK, Mørch LS, Brasso K, Kroman N, Larsen SB, Røder A, Stroomberg HV. PMID: 41782199 [PubMed - as supplied by publisher]
	Changes in perceived cognitive functioning following a codesigned online group cognitive rehabilitation for prostate cancer survivors on androgen deprivation therapy: Series of single-case experimental designs. Neuropsychol Rehabil Pembroke L, Sherman KA, Dhillon HM, Francis H, Gillatt D, Gurney H. PMID: 41781343 [PubMed - as supplied by publisher]
	Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-GuÃ©rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)' by R. Contieri et al. Ann Oncol Rouprêt M. PMID: 41781283 [PubMed - as supplied by publisher]
	Erratum to "Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review". [Cancer Treat. Rev. 140 (2025) 103024]. Cancer Treat Rev Charnley N, Fife K, Heng DYC, Larkin J, McGrane J, Négrier S, Vasudev N, Venugopal B, Chisholm A, Ogareva A, Prendergast Á, Albiges L. PMID: 41781237 [PubMed - as supplied by publisher]
	Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. J Immunother Cancer Jarrard D, Eickhoff J, Kyriakopoulos CE, Jeon D, Tonelli TP, Johnson L, Huang W, McNeel DG. PMID: 41781018 [PubMed - in process]
	Decoding the metabolic-immune axis for novel therapeutics in bladder cancer. Biochim Biophys Acta Rev Cancer Zhou M, Xue X, Li H, Chen Z, Nie Q, Lai Y. PMID: 41780575 [PubMed - as supplied by publisher]
	Prediction of Distant Metastasis in Renal Cell Carcinoma Using Machine Learning Algorithms: A Multicenter Cohort Study. Cancer Control Li Y, Wang X, Wang M, Shou J, Chen C, Wen L. PMID: 41779635 [PubMed - in process]
	[Treatment of metastatic hormone-sensitive prostate cancer]. Urologie Grimm MO, Leucht K, Marx M, Sperling M, Albarghouth MH. PMID: 41779146 [PubMed - as supplied by publisher]
	Single-cell transcriptomic profiling combined with Mendelian randomization illuminates molecular drivers of bladder cancer. Mol Genet Genomics He J, Jiang Z, Peng S, Peng L, Xia Z, Ma T, Tan X, Long Q, Wu J. PMID: 41779063 [PubMed - in process]
	Association of blood levels of forever plastics with lung cancer mortality among ever smokers in the Prostate Lung Colorectal and Ovarian (PLCO) cohort study. Clin Cancer Res Irajizad E, Fahrmann JF, Wu R, Rudsari H, Dennison JB, Ostrin E, Ajani J, Hanash S. PMID: 41779007 [PubMed - as supplied by publisher]
	Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC). Clin Cancer Res Slovin S, Gao X, Wei XX, Oh DY, McKay RR, Falchook G, Hussain A, McKean M, Wibmer A, Ho A, Eskew JD, Belani R, Coronella J, Haag S, Martin CE, McCaigue J, Mendoza J, Murphy A, Namini H, Spear MA, Shedlock DJ, Dorff TB. PMID: 41779004 [PubMed - as supplied by publisher]
	131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study. Clin Cancer Res Yu EY, Narayan V, Esposito G, Szmulewitz R, Lu Y, Lilly MB, Calais J, Bratslavsky G, Menda Y, Vasanawala M, Pouliot F, Laidley D, Fleshner N, Saad F, Provost JC, Teslenko I, Rawat NK, Ulaner G. PMID: 41779000 [PubMed - as supplied by publisher]
	PSMA PET/CT in diagnosing and staging high grade prostate cancer: accuracy and cost-effectiveness. Arch Ital Urol Androl Pepe P, Pepe L, Pepe G, Fiorentino V. PMID: 41778990 [PubMed - as supplied by publisher]
	Requirement for Written Informed Consent and Selection Bias in a Chart-Review Prostate Cancer Study. Am J Epidemiol Zheng R, Das SK, Tran TD, Friedrich NA, Cummings SM, Gonzalez A, De Hoedt AM, Bellerose H, Hoffmeyer A, Van de Ven TJ, Freedland SJ. PMID: 41778894 [PubMed - as supplied by publisher]
	Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility. Scand J Urol Pedersen TB, Poulsen CA, Lund M, Albitar M, Østergaard LD, Feddersen S, Lund L, Poulsen MH. PMID: 41778764 [PubMed - in process]
	Examining the prevalence and predictors of anxiety and depression across treatment stages in prostate cancer: a systematic review. Ecancermedicalscience Adesina OE, Akingbade O, Adesuyi EO, Tola Y, Adeyemi OB, Akintunde T, Osei S, Maitanmi J, Esan DT. PMID: 41778183 [PubMed]
	Label-free fluorescence lifetime imaging for rapid discrimination of high-grade prostate cancer in fresh biopsy cores: a feasibility study. J Biomed Opt Bec J, Zhou X, Tipirneni Y, Chen S, Qi J, Iczkowski KA, Dall'Era M, Marcu L. PMID: 41778026 [PubMed - in process]
	Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study. Cancer Invest Kondo H, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Takemori T, Kobayashi E, Higashi T, Kawai A. PMID: 41777120 [PubMed - as supplied by publisher]

Articles 1 - 20 / 185942

Page 1 of 9298



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy